On the other hand, pharmaceutical and genetic suppression of fatty acid synthase (FASN) has been shown not only to protect T cells from apoptosis within the TME triggered by repeated T cell receptor (TCR) activation but also to boost T cell immunity along with its antitumor efficacy on tumor cells [82,108]. The gene discussed is FASN; the disease is neoplasm.